Education
About Us
Working with TipRanks
Follow Us
RegenXBio Inc. (RGNX)
:RGNX
RGNX Stock Chart & Stats
$11.17
-$0.26(-3.11%)
At close: 4:00 PM EST
$11.17
-$0.26(-3.11%)
Day’s Range― - ―
52-Week Range$5.04 - $13.93
Previous CloseN/A
Volume155.59K
Average Volume (3M)620.02K
Market Cap
$586.47M
Enterprise ValueN/A
Total Cash (Recent Filing)$274.20M
Total Debt (Recent Filing)$76.51M
Price to Earnings (P/E)―
Beta2.23
Next Earnings
Mar 03, 2026EPS Estimate
-0.74Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.20
Shares Outstanding50,514,217
10 Day Avg. Volume520,963
30 Day Avg. Volume620,023
Financial Highlights & Ratios
PEG Ratio0.07
Price to Book (P/B)1.47
Price to Sales (P/S)4.59
P/FCF Ratio-2.18
Enterprise Value/Market Cap0.00
Enterprise Value/Revenue0.00
Enterprise Value/Gross Profit0.00
Enterprise Value/Ebitda0.00
Forecast
1Y Price Target
$24.13Price Target Upside116.03% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering9
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical Trial SuccessPositive data in NPDR warrant a pivotal trial, with significant improvements in the Phase 2 ALTITUDE trial of sura-vec gene therapy.
Manufacturing CapabilitiesRGNX’s modernized, scalable, and reproducible manufacturing capacity was confirmed by FDA inspections with no observations or issues, which is relatively unprecedented in the gene therapy space.
Regulatory SupportRGX-121 has received multiple designations from the FDA, including Orphan Drug and Fast Track, indicating strong regulatory support.
Bears Say
Commercial OpportunityShare impact will likely be muted as commercial opportunity in MPS II is modest and RGNX monetized the majority of its economic interest through strategic partnership with Nippon Shinyaku.
Extended Review TimelineFDA extended BLA review of clemidsogene lanparvovec (RGX-121) for Mucopolysaccharidosis II, pushing the PDUFA date to February 8, 2026.
Regulatory DelaysThe RGX-121 PDUFA was delayed primarily to review the submission of additional data requested by FDA.
RegenXBio News
RGNX FAQ
What was RegenXBio Inc.’s price range in the past 12 months?
RegenXBio Inc. lowest stock price was $5.04 and its highest was $13.93 in the past 12 months.
What is RegenXBio Inc.’s market cap?
RegenXBio Inc.’s market cap is $586.47M.
When is RegenXBio Inc.’s upcoming earnings report date?
RegenXBio Inc.’s upcoming earnings report date is Mar 03, 2026 which is in 115 days.
How were RegenXBio Inc.’s earnings last quarter?
RegenXBio Inc. released its earnings results on Nov 06, 2025. The company reported -$1.2 earnings per share for the quarter, beating the consensus estimate of -$1.282 by $0.082.
Is RegenXBio Inc. overvalued?
According to Wall Street analysts RegenXBio Inc.’s price is currently Undervalued.
Does RegenXBio Inc. pay dividends?
RegenXBio Inc. does not currently pay dividends.
What is RegenXBio Inc.’s EPS estimate?
RegenXBio Inc.’s EPS estimate is -0.74.
How many shares outstanding does RegenXBio Inc. have?
RegenXBio Inc. has 50,514,217 shares outstanding.
What happened to RegenXBio Inc.’s price movement after its last earnings report?
RegenXBio Inc. reported an EPS of -$1.2 in its last earnings report, beating expectations of -$1.282. Following the earnings report the stock price went down -3.79%.
Which hedge fund is a major shareholder of RegenXBio Inc.?
Currently, no hedge funds are holding shares in RGNX
RegenXBio Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$24.13 (116.03% Upside)
$24.13 (116.03% Upside)
Blogger Sentiment
Bullish
RGNX Sentiment 70%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Increased
By 58.1K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▼ 1.2%
Last 30 Days ▲ 7.5%
Last 30 Days ▲ 7.5%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
18.45%
12-Months-Change
Fundamentals
Return on Equity
-62.49%
Trailing 12-Months
Asset Growth
2.05%
Trailing 12-Months
Company Description
RegenXBio Inc.
RegenXBio Inc. is a biotechnology company focused on developing gene therapies for the treatment of various genetic diseases and disorders. The company specializes in its proprietary adeno-associated virus (AAV) gene therapy platform, which is designed to provide long-lasting therapeutic effects by delivering genetic material directly to target cells. RegenXBio's core products include treatments for conditions such as X-linked retinitis pigmentosa, spinal muscular atrophy, and other rare genetic disorders, positioning the company at the forefront of the growing gene therapy market.
RGNX Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call highlighted significant progress and achievements in clinical development and financial positioning. However, there are regulatory challenges and uncertainties, particularly concerning international approvals and the use of external controls. Despite these challenges, the overall sentiment leans positive due to strong pipeline advancements and financial stability.View all RGNX earnings summariesRGNX Stock 12 Month Forecast
Average Price Target
$24.13
▲(116.03% Upside)
Technical Analysis
Solid Biosciences
―
Monopar Therapeutics Inc
―
Opthea Limited Sponsored ADR
―
Monte Rosa Therapeutics
―
Inhibrx Biosciences Inc
―
Ownership Overview
8.70% Insiders
19.54% Mutual Funds
1.51% Other Institutional Investors
56.91% Public Companies and Individual Investors